Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
TCC announced a webinar featuring former Icahn Enterprises CEO Aris Kekedjian and Stanford professor Dr. Yossi Feinberg, focusing on strategies to navigate potential recession impacts in 2023. The event addresses rising interest rates, inflation risks, and supply chain disruptions, emphasizing the need for business leaders to maintain corporate value through proactive measures. Scheduled for February 2, 2023, at 8 am PST, the panel will include audience participation for real-time questions. TCC aims to provide insights that mitigate risks and leverage innovation for corporate leadership during challenging economic times.
The lateral flow assays market is projected to grow at a CAGR of 3% from 2023 to 2028, reaching a market size of USD 11.30 billion by 2028, up from USD 9.53 billion in 2022. Key drivers include smartphone and AI integration, increased applications in food & beverage testing, and rising demand for home-based testing devices, particularly amid the COVID-19 pandemic. Major players in the market include Trinity Biotech, Abbott, Roche, and Thermo Fisher Scientific. This growth reflects heightened awareness and adoption of point-of-care testing solutions.
The in-vitro diagnostics market in North America is expected to grow at a CAGR of 3.3% from 2022 to 2028, highlighting significant investment opportunities exceeding USD 3 trillion. In 2022, North America held the largest market share at 40% globally, driven by high healthcare expenditure and a patient population with chronic conditions (60%-80%) demanding diagnostic services. The market size is projected to reach USD 127.56 billion by 2028 from USD 105 billion in 2022. The COVID-19 pandemic accelerated the demand for IVD solutions, especially point-of-care diagnostics, emphasizing the growing importance of rapid testing and new product launches.
The global HIV rapid test kits market is projected to grow from
The Global Rapid Diagnostics Market is projected to reach $77.1 billion by 2031, expanding at a 7.4% CAGR from 2021. Key growth drivers include increased demand for point-of-care diagnostics, rising chronic diseases, and a growing elderly population. The report provides a detailed analysis of market structure, growth drivers, and emerging trends across key product segments such as consumables and analyzers. It also outlines market opportunities across various applications including blood glucose and infectious disease testing. This comprehensive outlook covers regional insights and competitive landscape.
Trade Capital Corporation (TCC) has released its 2023 Economic Outlook, indicating significant risks for the U.S. economy, including inflation and demand compression as it heads toward a potential recession. TCC predicts muted GDP growth and ongoing supply chain disruptions, exacerbated by the Russo-Ukraine war. The report emphasizes the necessity for corporate leaders to enhance resilience and embrace capital-efficient business models. CEO Sanjay Bonde urges companies to preserve liquidity and adapt to rising costs. An online event discussing these strategies will occur on February 2, 2023.
Trinity Biotech (Nasdaq: TRIB) has announced a strategic partnership with imaware Inc to enhance digital health solutions through at-home and remote testing programs. As part of this partnership, Trinity Biotech will invest $1.5M in convertible notes and serve as imaware's lab testing partner for five years. They aim to process over 650,000 test kits annually by year three, focusing on integrated solutions for digital health partners. Both companies plan to innovate their offerings to provide effective testing services to patients, providers, and health systems.
Trinity Biotech (TRIB) reported Q3 2022 revenues of $19.5 million, reflecting an 11.4% decline from $22.0 million in Q3 2021. Excluding Covid-related products, revenues increased by 2% YoY. Haemoglobin and Fitzgerald Industries sectors drove a 30% revenue increase. Gross profit fell to $2.0 million (10.3% margin), impacted by $4.7 million in inventory write-downs. Operating loss was $7.1 million, a significant decrease compared to last year. Cash reserves decreased to $7.3 million from $10.5 million at Q2 2022. The company continues to develop new diagnostic products, targeting launches in 2023.
Trinity Biotech (Nasdaq: TRIB) will report its third quarter fiscal year 2022 financial results on December 15, 2022. A conference call discussing these results is scheduled for the same day at 11:00 am ET. Interested participants can join the call via US toll-free at 1-844-861-5499 or access the webcast online. The results will be crucial for investors to gauge the company's performance in the diagnostic products sector. Trinity Biotech develops diagnostic systems for infectious diseases and other health parameters, selling directly in major markets and through international distributors.
Dublin-based Trinity Biotech (Nasdaq: TRIB) is set to participate in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022. CEO Aris Kekedjian and CFO John Gillard will present at 10:30 AM ET and will hold individual meetings with investors. A webcast of the presentation will be available for three months. Trinity Biotech specializes in diagnostic products for point-of-care and clinical laboratory markets, supplying over 75 countries with its systems to detect infectious diseases and measure Haemoglobin A1c levels.